Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368445 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 617
- Enrollment target
NCT01368445 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 617 participants.
The verdict
NCT01368445, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 617 participants
- Enrollment target
Study Summary
The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis.
Interventions
- DRUG azelastine hydrochloride 0.15% Nasal Spray
- DRUG azelastine hydrochloride 0.15% and Placebo
- DRUG Azelastine 0.1%, Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01368445
The ClinicalTrials.gov registry entry for NCT01368445 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 617 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which azelastine hydrochloride 0.15% Nasal Spray is the first listed.
NCT01368445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01368445 about?
NCT01368445 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies". The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis.
What is the current status of trial NCT01368445?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 617 participants. The study started on 2006-08. Estimated completion is 2008-04.
What interventions are being tested in trial NCT01368445?
The interventions under investigation include: azelastine hydrochloride 0.15% Nasal Spray (DRUG), azelastine hydrochloride 0.15% and Placebo (DRUG), Azelastine 0.1%, Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT01368445?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.